baha the information company

baha is a leading provider of real-time market data, financial news, technology and solutions for the financial industry. baha offers real-time data terminals for professionals, global financial market data covering over 12 million financial instruments on more than 150 exchanges, as well as 24/7 breaking news with global coverage and free web and mobile apps. From a total of around 200 real-time data providers worldwide, only Reuters 1851, Bloomberg 1981 and now baha in 2021 were named after the founder.

Medicinova/ US58468P2065 /

5/20/2024 9:53:02 PM	Chg. -0.06	Volume	Bid-	Ask-	High	Low
1.38USD	-4.17%	1 Turnover: 1.38	-Bid Size: -	-Ask Size: -	1.38	1.38

GlobeNewswire 5/20 MediciNova Receives Notice of Allowance for New Patent Covering MN-166 (ibudilast) for the Preventio...

GlobeNewswire 5/14 MediciNova Receives Notice of Allowance for New Patent Covering MN-166 (ibudilast) for the Treatment...

GlobeNewswire 5/7 MediciNova Receives Issue Notification for New Patent Covering Extended-Release Formulations of MN-1...

GlobeNewswire 4/3 MediciNova Announces Abstract Regarding Results of a Clinical Trial of MN-166 (ibudilast) in Gliobla...

GlobeNewswire 3/27 MediciNova Receives a Notice of Allowance for a New Patent Covering MN-166 (ibudilast) for the Treat...

GlobeNewswire 3/21 MediciNova Announces Two Abstracts regarding MN-001 (tipelukast) and MN-002 Accepted for Presentatio...

GlobeNewswire 3/12 MediciNova Announces New Data and Results of MN-166 (ibudilast) in Chlorine Gas-induced Acute Lung I...

GlobeNewswire 1/17 MediciNova Receives a Notice of Grant for a New Patent Covering MN-166 (ibudilast) for the Treatment...

GlobeNewswire 12/22/2023 MediciNova Announces Abstract Regarding MN-166 (ibudilast) in Chlorine Gas-induced Lung Injury Accep...

GlobeNewswire 12/7/2023 MediciNova Receives a Notice of Decision to Grant for a New Patent Covering MN-166 (ibudilast) for t...

GlobeNewswire 11/20/2023 MediciNova Announces New Data and Results of a Phase 2 Clinical Trial of MN-166 (ibudilast) in Gliob...

GlobeNewswire 10/27/2023 MediciNova’s Collaborator Initiates Clinical Development of a Gene Therapy Product for the Treatment...

GlobeNewswire 10/11/2023 MediciNova Receives a Notice of Allowance for a New Patent Covering the Combination of MN-166 (ibudi...

GlobeNewswire 10/5/2023 MediciNova Receives Gene Therapy Milestone Payment

GlobeNewswire 9/28/2023 MediciNova Announces Results of Studies under BARDA Contract to Develop MN 166 (ibudilast) as a Medi...

GlobeNewswire 8/18/2023 MediciNova Announces Abstract Regarding MN-166 (ibudilast) in Glioblastoma Accepted for Presentation...

GlobeNewswire 8/17/2023 MediciNova Receives a Notice of Intention to Grant for a New Patent Covering MN-166 (ibudilast) for ...

GlobeNewswire 8/16/2023 MediciNova Receives a New Patent Covering MN-001 for the Treatment of Scleroderma and Systemic Scler...

GlobeNewswire 3/17/2022 MediciNova Receives Notice of Allowance for New Patent Covering MN-001 and MN-002 for the Treatment ...

GlobeNewswire 3/15/2022 MediciNova to Participate in the 2022 Virtual Growth Conference Presented by Maxim Group LLC and hos...

GlobeNewswire 2/28/2022 MediciNova Announces MN-166 (ibudilast) Identified as Potential Beneficial Pharmacotherapy for Treat...

GlobeNewswire 2/22/2022 MediciNova Announces MN-166 (ibudilast) Identified as Promising Pharmacotherapy for Alcohol Use Diso...

GlobeNewswire 1/31/2022 MediciNova Receives a Notice of Allowance for a New Patent Covering MN-001 and MN-002 for Hepatic Ba...

GlobeNewswire 1/27/2022 MediciNova Receives a Notice of Intention to Grant for a New Patent Covering MN-166 (ibudilast) for ...

GlobeNewswire 1/26/2022 MediciNova Receives a Notice of Intention to Grant for a New Patent Covering MN-001 and MN-002 for H...

Medicinova/ US58468P2065 /

If you wish to receive reply to your feedback, please provide your email address.